Literature DB >> 7531143

Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7.

A Hill1, A Worth, T Elliott, S Rowland-Jones, J Brooks, A Rickinson, A McMichael.   

Abstract

We have identified two epitopes for Epstein-Barr virus specific cytotoxic T lymphocytes (CTL) restricted by the common allele HLA-B7. They are EBNA 3C 881-9 (QPRAPIRPI) and EBNA 3A 379-387 (RPPIFIRRL). The epitopes conform well to the recently described motif for HLA-B7-binding peptides (Huckzo et al., J. Immunol. 1993. 151:2572). Titration of the peptides in CTL assays and detergent lysate binding assays revealed that extending the peptides at either the N or C terminus did not reduce their affinity for HLA-B7. This behavior contrasted with HLA-B51, which binds peptides with a similar motif to B7, and has identical amino acid residues at sites expected to form the "F" pocket of the peptide-binding groove. HLA-B51 also bound the peptide EBNA 3C 881-9, but was unable to bind peptides extended at the C terminus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531143     DOI: 10.1002/eji.1830250105

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  The oxidoreductase ERp57 efficiently reduces partially folded in preference to fully folded MHC class I molecules.

Authors:  Antony N Antoniou; Stuart Ford; Magnus Alphey; Andrew Osborne; Tim Elliott; Simon J Powis
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

3.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

4.  Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.

Authors:  R Khanna; S R Burrows; D J Moss; S L Silins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 5.  The interplay between HLA-B27 and ERAP1/ERAP2 aminopeptidases: from anti-viral protection to spondyloarthritis.

Authors:  C Vitulano; V Tedeschi; F Paladini; R Sorrentino; M T Fiorillo
Journal:  Clin Exp Immunol       Date:  2017-08-30       Impact factor: 4.330

6.  Alloreactive cytotoxic T-lymphocyte-defined HLA-B7 subtypes differ in peptide antigen presentation.

Authors:  K D Smith; D F Epperson; C T Lutz
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

7.  The use of bovine MHC class I allele-specific peptide motifs and proteolytic cleavage specificities for the prediction of potential cytotoxic T lymphocyte epitopes of bovine viral diarrhea virus.

Authors:  N R Hegde; S Srikumaran
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

8.  A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

Authors:  S M Morgan; G W Wilkinson; E Floettmann; N Blake; A B Rickinson
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution.

Authors:  J M Burrows; S R Burrows; L M Poulsen; T B Sculley; D J Moss; R Khanna
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Lack of immune responses against multiple sclerosis-associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosis.

Authors:  Klemens Ruprecht; Felix Gronen; Marlies Sauter; Barbara Best; Peter Rieckmann; Nikolaus Mueller-Lantzsch
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.